The Role of Short-Chain Fatty Acids in Health and Disease

Advances in Immunology

Volumn 121, Issue , 2014, Pages 91-119

  Tan, Jian ^a   McKenzie, Craig ^a   Potamitis, Maria ^a   Thorburn, Alison N ^a   Mackay, Charles R ^a   Macia, Laurence ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Fiber; G protein coupled receptor; Histone deacetylases; Microbiota; Short chain fatty acids

Indexed keywords

ACETIC ACID; BUTYRIC ACID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109A; G PROTEIN COUPLED RECEPTOR 41; G PROTEIN COUPLED RECEPTOR 43; HISTONE DEACETYLASE; MONOCARBOXYLATE TRANSPORTER 1; PREBIOTIC AGENT; PROBIOTIC AGENT; PROPIONIC ACID; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CHEMOTAXIS; COLON CANCER; COLORECTAL CANCER; CROHN DISEASE; DIET SUPPLEMENTATION; ENTERIC COATED TABLET; ENTEROPATHY; ENZYME INHIBITION; ESSENTIAL FATTY ACID DEFICIENCY; FATTY ACID ANALYSIS; FATTY ACID SYNTHESIS; FATTY ACID TRANSPORT; HUMAN; IMMUNE DYSREGULATION; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE FLORA; LIPID DIET; METABOLIC REGULATION; MUCOSA INFLAMMATION; NEOPLASM; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SALMONELLOSIS; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

FIBER; G-PROTEIN-COUPLED RECEPTOR; HISTONE DEACETYLASES; MICROBIOTA; SHORT-CHAIN FATTY ACIDS;

ANIMALS; CYTOKINES; FATTY ACIDS, VOLATILE; HISTONE DEACETYLASE INHIBITORS; HUMANS; INFLAMMATION; MICROBIOTA; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 84891363464     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800100-4.00003-9     Document Type: Chapter

References (133)

1. Akimova T., Ge G., Golovina T., Mikheeva T., Wang L., Riley J.L., et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clinical Immunology 2010, 136:348.
2. Akolkar P.N., Gulwani-Akolkar B., Heresbach D., Lin X.Y., Fisher S., Katz S., et al. Differences in risk of Crohn's disease in offspring of mothers and fathers with inflammatory bowel disease. The American Journal of Gastroenterology 1997, 92:2241.
3. Alva-Murillo N., Ochoa-Zarzosa A., Lopez-Meza J.E. Short chain fatty acids (propionic and hexanoic) decrease Staphylococcus aureus internalization into bovine mammary epithelial cells and modulate antimicrobial peptide expression. Veterinary Microbiology 2012, 155:324.
4. Aoyama M., Kotani J., Usami M. Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. Nutrition 2010, 26:653.
5. Arora T., Sharma R., Frost G. Propionate. Anti-obesity and satiety enhancing factor?. Appetite 2011, 56:511.
6. Ashburner B.P., Westerheide S.D., Baldwin A.S. The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Molecular and Cellular Biology 2001, 21:7065.
7. Aune D., Chan D.S., Lau R., Vieira R., Greenwood D.C., Kampman E., et al. Dietary fibre, whole grains, and risk of colorectal cancer: Systematic review and dose-response meta-analysis of prospective studies. BMJ 2011, 343:d6617.
8. Balasubramanian S., Ramos J., Luo W., Sirisawad M., Verner E., Buggy J.J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008, 22:1026.
9. Balda M.S., Matter K. Tight junctions at a glance. Journal of Cell Science 2008, 121:3677.
10. Bermudez Y., Benavente C.A., Meyer R.G., Coyle W.R., Jacobson M.K., Jacobson E.L. Nicotinic acid receptor abnormalities in human skin cancer: Implications for a role in epidermal differentiation. PLoS One 2011, 6:e20487.
11. Boffa L.C., Vidali G., Mann R.S., Allfrey V.G. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. Journal of Biological Chemistry 1978, 253:3364.
12. Borody T.J., Brandt L.J., Paramsothy S., Agrawal G. Fecal microbiota transplantation: A new standard treatment option for Clostridium difficile infection. Expert Review of Anti-Infective Therapy 2013, 11:447.
13. Borthakur A., Priyamvada S., Kumar A., Natarajan A.A., Gill R.K., Alrefai W.A., et al. A novel nutrient sensing mechanism underlies substrate-induced regulation of monocarboxylate transporter-1. American Journal of Physiology. Gastrointestinal and Liver Physiology 2012, 303:G1126.
14. Böttcher M.F., Nordin E.K., Sandin A., Midtvedt T., Björkstén B. Microflora-associated characteristics in faeces from allergic and nonallergic infants. Clinical & Experimental Allergy 2000, 30:1591.
15. Brandt L.J. Fecal transplantation for the treatment of Clostridium difficile infection. Gastroenterology & Hepatology (N Y) 2012, 8:191.
16. Brown C.T., Davis-Richardson A.G., Giongo A., Gano K.A., Crabb D.B., Mukherjee N., et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS ONE 2011, 6:e25792.
17. Bruna Barneda-Zahonero L.R.-G., Collazo Olga, Rafati Haleh, Abul B.M.M.K., Islam Lars H., di Tullio Bussmann Alessandro, et al. HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages. PLOS Genetics 2013, 9.
18. Burger-van Paassen N., Vincent A., Puiman P.J., van der Sluis M., Bouma J., Boehm G., et al. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: Implications for epithelial protection. The Biochemical Journal 2009, 420:211.
19. Cavaglieri C.R., Nishiyama A., Fernandes L.C., Curi R., Miles E.A., Calder P.C. Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes. Life Sciences 2003, 73:1683.
20. Chen L.-F., Fischle W., Verdin E., Greene W.C. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001, 293:1653.
21. Cherbut C., Ferrier L., Roze C., Anini Y., Blottiere H., Lecannu G., et al. Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat. The American Journal of Physiology 1998, 275:G1415.
22. Cousens L.S., Gallwitz D., Alberts B.M. Different accessibilities in chromatin to histone acetylase. The Journal of Biological Chemistry 1979, 254:1716.
23. Cox M.A., Jackson J., Stanton M., Rojas-Triana A., Bober L., Laverty M., et al. Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E(2) and cytokines. World Journal of Gastroenterology 2009, 15:5549.
24. Cronin M., Ventura M., Fitzgerald G.F., van Sinderen D. Progress in genomics, metabolism and biotechnology of bifidobacteria. International Journal of Food Microbiology 2011, 149:4.
25. Damman C.J., Miller S.I., Surawicz C.M., Zisman T.L. The microbiome and inflammatory bowel disease: Is there a therapeutic role for fecal microbiota transplantation?. The American Journal of Gastroenterology 2012, 107:1452.
26. Davidson A.L., Chen J. ATP-binding cassette transporters in bacteria. Annual Review of Biochemistry 2004, 73:241.
27. Davie J.R. Inhibition of histone deacetylase activity by butyrate. Journal of Nutrition 2003, 133:2485S.
28. De Filippo C., Cavalieri D., Di Paola M., Ramazzotti M., Poullet J.B., Massart S., et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:14691.
29. Dewulf E.M., Cani P.D., Neyrinck A.M., Possemiers S., Van Holle A., Muccioli G.G., et al. Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPARgamma-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. The Journal of Nutritional Biochemistry 2011, 22:712.
30. Dewulf E.M., Ge Q., Bindels L.B., Sohet F.M., Cani P.D., Brichard S.M., et al. Evaluation of the relationship between GPR43 and adiposity in human. Nutrition & Metabolism (London) 2013, 10:11.
31. Donohoe D.R., Garge N., Zhang X., Sun W., O'Connell T.M., Bunger M.K., et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metabolism 2011, 13:517.
32. Duncan S.H., Holtrop G., Lobley G.E., Calder A.G., Stewart C.S., Flint H.J. Contribution of acetate to butyrate formation by human faecal bacteria. The British Journal of Nutrition 2004, 91:915.
33. Englyst H.N., Kingman S.M., Cummings J.H. Classification and measurement of nutritionally important starch fractions. European Journal of Clinical Nutrition 1992, 46(Suppl. 2):S33.
34. Fast A.G., Papoutsakis E.T. Stoichiometric and energetic analyses of non-photosynthetic CO2-fixation pathways to support synthetic biology strategies for production of fuels and chemicals. Current Opinion in Chemical Engineering 2012, 1:380.
35. Fernandez-Rubio C., Ordonez C., Abad-Gonzalez J., Garcia-Gallego A., Honrubia M.P., Mallo J.J., et al. Butyric acid-based feed additives help protect broiler chickens from Salmonella Enteritidis infection. Poultry Science 2009, 88:943.
36. Ferreira T.M., Leonel A.J., Melo M.A., Santos R.R., Cara D.C., Cardoso V.N., et al. Oral supplementation of butyrate reduces mucositis and intestinal permeability associated with 5-Fluorouracil administration. Lipids 2012, 47:669.
37. Fontenelle B., Gilbert K.M. n-Butyrate anergized effector CD4+ T cells independent of regulatory T cell generation or activity. Scandinavian Journal of Immunology 2012, 76:457.
38. Frank D.N., St.Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the National Academy of Sciences 2007, 104:13780.
39. Fukuda S., Toh H., Hase K., Oshima K., Nakanishi Y., Yoshimura K., et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011, 469:543.
40. Ganapathy V., Gopal E., Miyauchi S., Prasad P.D. Biological functions of SLC5A8, a candidate tumour suppressor. Biochemical Society Transactions 2005, 33:237.
41. Guilloteau P., Martin L., Eeckhaut V., Ducatelle R., Zabielski R., Van Immerseel F. From the gut to the peripheral tissues: The multiple effects of butyrate. Nutrition Research Reviews 2010, 23:366.
42. Gupta N., Martin P.M., Prasad P.D., Ganapathy V. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sciences 2006, 78:2419.
43. Halestrap A.P., Wilson M.C. The monocarboxylate transporter family-Role and regulation. IUBMB Life 2012, 64:109.
44. Hamer H.M., Jonkers D., Venema K., Vanhoutvin S., Troost F.J., Brummer R.J. Review article: The role of butyrate on colonic function. Alimentary Pharmacology & Therapeutics 2008, 27:104.
45. Hayden M.S., West A.P., Ghosh S. NF-kappaB and the immune response. Oncogene 2006, 25:6758.
46. Herold S., Paton J.C., Srimanote P., Paton A.W. Differential effects of short-chain fatty acids and iron on expression of iha in Shiga-toxigenic Escherichia coli. Microbiology 2009, 155:3554.
47. Hijazi Z., Molla A.M., Al-Habashi H., Muawad W.M., Molla A.M., Sharma P.N. Intestinal permeability is increased in bronchial asthma. Archives of Disease in Childhood 2004, 89:227.
48. Hinnebusch B.F., Meng S., Wu J.T., Archer S.Y., Hodin R.A. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. The Journal of Nutrition 2002, 132:1012.
49. Hong Y.H., Nishimura Y., Hishikawa D., Tsuzuki H., Miyahara H., Gotoh C., et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology 2005, 146:5092.
50. Hoverstad T., Midtvedt T. Short-chain fatty acids in germfree mice and rats. The Journal of Nutrition 1986, 116:1772.
51. Huda-Faujan N., Abdulamir A.S., Fatimah A.B., Anas O.M., Shuhaimi M., Yazid A.M., et al. The impact of the level of the intestinal short chain Fatty acids in inflammatory bowel disease patients versus healthy subjects. The Open Biochemistry Journal 2010, 4:53.
52. Ingersoll M.A., Potteaux S., Alvarez D., Hutchison S.B., van Rooijen N., Randolph G.J. Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis. Immunobiology 2012, 5:548-557.
53. Iwanaga T., Takebe K., Kato I., Karaki S., Kuwahara A. Cellular expression of monocarboxylate transporters (MCT) in the digestive tract of the mouse, rat, and humans, with special reference to slc5a8. Biomedical Research 2006, 27:243.
54. Kang I., Kim S.W., Youn J.H. Effects of nicotinic acid on gene expression: Potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug. The Journal of Clinical Endocrinology and Metabolism 2011, 96:3048.
55. Karaki S., Tazoe H., Hayashi H., Kashiwabara H., Tooyama K., Suzuki Y., et al. Expression of the short-chain fatty acid receptor, GPR43, in the human colon. Journal of Molecular Histology 2008, 39:135.
56. Kendrick S.F.W., O'Boyle G., Mann J., Zeybel M., Palmer J., Jones D.E.J., et al. Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. Hepatology 2010, 51:1988.
57. Kida Y., Shimizu T., Kuwano K. Sodium butyrate up-regulates cathelicidin gene expression via activator protein-1 and histone acetylation at the promoter region in a human lung epithelial cell line, EBC-1. Molecular Immunology 2006, 43:1972.
58. Kiefer J., Beyer-Sehlmeyer G., Pool-Zobel B.L. Mixtures of SCFA, composed according to physiologically available concentrations in the gut lumen, modulate histone acetylation in human HT29 colon cancer cells. The British Journal of Nutrition 2006, 96:803.
59. Kim H.J., Bae S.C. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. American Journal of Translational Research 2011, 3:166.
60. Kimura I., Inoue D., Maeda T., Hara T., Ichimura A., Miyauchi S., et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proceedings of the National Academy of Sciences of the United States of America 2011, 108:8030.
61. King D.E., Mainous A.G., Lambourne C.A. Trends in dietary fiber intake in the United States, 1999-2008. Journal of the Academy of Nutrition and Dietetics 2012, 112:642.
62. Kong X., Fang M., Li P., Fang F., Xu Y. HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells. Journal of Molecular and Cellular Cardiology 2009, 46:292.
63. Lal G., Bromberg J.S. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 2009, 114:3727.
64. Le Poul E., Loison C., Struyf S., Springael J.Y., Lannoy V., Decobecq M.E., et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. The Journal of Biological Chemistry 2003, 278:25481.
65. Li N., Hatch M., Wasserfall C.H., Douglas-Escobar M., Atkinson M.A., Schatz D.A., et al. Butyrate and type 1 diabetes mellitus: Can we fix the intestinal leak?. Journal of Pediatric Gastroenterology and Nutrition 2010, 51:414.
66. Li X., Millar J.S., Brownell N., Briand F., Rader D.J. Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes. Biochemical Pharmacology 2010, 80:1450.
67. Li B., Samanta A., Song X., Iacono K.T., Bembas K., Tao R., et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:4571.
68. Lu J., Sun H., Wang X., Liu C., Xu X., Li F., et al. Interleukin-12 p40 promoter activity is regulated by the reversible acetylation mediated by HDAC1 and p300. Cytokine 2005, 31:46.
69. Lucas J.L., Mirshahpanah P., Haas-Stapleton E., Asadullah K., Zollner T.M., Numerof R.P. Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cellular Immunology 2009, 257:97.
70. MacDonald V.E., Howe L.J. Histone acetylation: Where to go and how to get there. Epigenetics 2009, 4:139.
71. Macfarlane S., Macfarlane G.T. Regulation of short-chain fatty acid production. The Proceedings of the Nutrition Society 2003, 62:67.
72. Macia L., Thorburn A.N., Binge L.C., Marino E., Rogers K.E., Maslowski K.M., et al. Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. Immunological Reviews 2012, 245:164.
73. Mahowald M.A., Rey F.E., Seedorf H., Turnbaugh P.J., Fulton R.S., Wollam A., et al. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:5859.
74. Marchesi J.R., Holmes E., Khan F., Kochhar S., Scanlan P., Shanahan F., et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. Journal of Proteome Research 2007, 6:546.
75. Maslowski K.M., Mackay C.R. Diet, gut microbiota and immune responses. Nature Immunology 2011, 12:5.
76. Maslowski K.M., Vieira A.T., Ng A., Kranich J., Sierro F., Yu D., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461:1282.
77. Mennigen R., Nolte K., Rijcken E., Utech M., Loeffler B., Senninger N., et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. American Journal of Physiology. Gastrointestinal and Liver Physiology 2009, 296:G1140.
78. Miller T.L., Wolin M.J. Pathways of acetate, propionate, and butyrate formation by the human fecal microbial flora. Applied and Environmental Microbiology 1996, 62:1589.
79. Miyauchi S., Gopal E., Fei Y.J., Ganapathy V. Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na(+)-coupled transporter for short-chain fatty acids. The Journal of Biological Chemistry 2004, 279:13293.
80. Nakamura M., Saito H., Ebinuma H., Wakabayashi K., Saito Y., Takagi T., et al. Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor. Journal of Cellular Physiology 2001, 187:392.
81. Nakanishi N., Tashiro K., Kuhara S., Hayashi T., Sugimoto N., Tobe T. Regulation of virulence by butyrate sensing in enterohaemorrhagic Escherichia coli. Microbiology 2009, 155:521.
82. Ni Y.F., Wang J., Yan X.L., Tian F., Zhao J.B., Wang Y.J., et al. Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in mice. Respiratory Research 2010, 11:33.
83. Pan X.D., Chen F.Q., Wu T.X., Tang H.G., Zhao Z.Y. Prebiotic oligosaccharides change the concentrations of short-chain fatty acids and the microbial population of mouse bowel. Journal of Zhejiang University. Science. B 2009, 10:258.
84. Park Y., Subar A.F., Hollenbeck A., Schatzkin A. Dietary fiber intake and mortality in the NIH-AARP diet and health study. Archives of Internal Medicine 2011, 171:1061.
85. Perrier C., Corthesy B. Gut permeability and food allergies. Clinical and Experimental Allergy 2011, 41:20.
86. Pokusaeva K., Fitzgerald G.F., van Sinderen D. Carbohydrate metabolism in Bifidobacteria. Genes & Nutrition 2011, 6:285.
87. Pomare E.W., Branch W.J., Cummings J.H. Carbohydrate fermentation in the human colon and its relation to acetate concentrations in venous blood. The Journal of Clinical Investigation 1985, 75:1448.
88. Postma P.W., Lengeler J.W., Jacobson G.R. Phosphoenolpyruvate:carbohydrate phosphotransferase systems of bacteria. Microbiological Reviews 1993, 57:543.
89. Ragsdale S.W., Pierce E. Acetogenesis and the Wood-Ljungdahl pathway of CO(2) fixation. Biochimica et Biophysica Acta 2008, 1784:1873.
90. Roelofsen H., Priebe M.G., Vonk R.J. The interaction of short-chain fatty acids with adipose tissue: Rlevance for prevention of type 2 diabetes. Beneficial Microbes 2010, 1:433.
91. Roy C.C., Kien C.L., Bouthillier L., Levy E. Short-chain fatty acids: Ready for prime time?. Nutrition in Clinical Practice 2006, 21:351.
92. Sabatino A.D., Morera R., Ciccocioppo R., Cazzola P., Gotti S., Tinozzi F.P., et al. Oral butyrate for mildly to moderately active Crohn's disease. Alimentary Pharmacology & Therapeutics 2005, 22:789.
93. Saemann M.D., Bohmig G.A., Osterreicher C.H., Burtscher H., Parolini O., Diakos C., et al. Anti-inflammatory effects of sodium butyrate on human monocytes: Potent inhibition of IL-12 and up-regulation of IL-10 production. The FASEB Journal 2000, 14:2380.
94. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics. Gastroenterology 2004, 126:1620.
95. Sealy L., Chalkley R. The effect of sodium butyrate on histone modification. Cell 1978, 14:115.
96. Segain J.P., Raingeard de la Bletiere D., Bourreille A., Leray V., Gervois N., Rosales C., et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: Implications for Crohn's disease. Gut 2000, 47:397.
97. Sellon R.K., Tonkonogy S., Schultz M., Dieleman L.A., Grenther W., Balish E., et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infection and Immunity 1998, 66:5224.
98. Senga T., Iwamoto S., Yoshida T., Yokota T., Adachi K., Azuma E., et al. LSSIG is a novel murine leukocyte-specific GPCR that is induced by the activation of STAT3. Blood 2003, 101:1185.
99. Shapira Y., Agmon-Levin N., Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. Journal of Autoimmunity 2010, 34:J168.
100. Singh N., Thangaraju M., Prasad P.D., Martin P.M., Lambert N.A., Boettger T., et al. Blockade of dendritic cell development by bacterial fermentation products butyrate and propionate through a transporter (Slc5a8)-dependent inhibition of histone deacetylases. The Journal of Biological Chemistry 2010, 285:27601.
101. Sleeth M.L., Thompson E.L., Ford H.E., Zac-Varghese S.E., Frost G. Free fatty acid receptor 2 and nutrient sensing: A proposed role for fibre, fermentable carbohydrates and short-chain fatty acids in appetite regulation. Nutrition Research Reviews 2010, 23:135.
102. Soliman M.L., Rosenberger T.A. Acetate supplementation increases brain histone acetylation and inhibits histone deacetylase activity and expression. Molecular and Cellular Biochemistry 2011, 352:173.
103. Sunkara L.T., Jiang W., Zhang G. Modulation of antimicrobial host defense peptide gene expression by free fatty acids. PLoS One 2012, 7:e49558.
104. Suzuki T., Yoshida S., Hara H. Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. The British Journal of Nutrition 2008, 100:297.
105. Tang Y., Chen Y., Jiang H., Robbins G.T., Nie D. G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer. International Journal of Cancer 2011, 128:847.
106. Tang D., Kang R., Zeh Iii H.J., Lotze M.T. High-mobility group box 1 and cancer. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 2010, 1799:131.
107. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nature Medicine 2007, 13:1299.
108. Tazoe H., Otomo Y., Kaji I., Tanaka R., Karaki S.I., Kuwahara A. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. Journal of Physiology and Pharmacology 2008, 59(Suppl. 2):251.
109. Tazoe H., Otomo Y., Karaki S., Kato I., Fukami Y., Terasaki M., et al. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomedical Research 2009, 30:149.
110. Tedelind S., Westberg F., Kjerrulf M., Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: A study with relevance to inflammatory bowel disease. World Journal of Gastroenterology 2007, 13:2826.
111. Thangaraju M., Cresci G.A., Liu K., Ananth S., Gnanaprakasam J.P., Browning D.D., et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Research 2009, 69:2826.
112. Tobe T., Nakanishi N., Sugimoto N. Activation of motility by sensing short-chain fatty acids via two steps in a flagellar gene regulatory cascade in enterohemorrhagic Escherichia coli. Infection and Immunity 2011, 79:1016.
113. Tolhurst G., Heffron H., Lam Y.S., Parker H.E., Habib A.M., Diakogiannaki E., et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012, 61:364.
114. Usami M., Kishimoto K., Ohata A., Miyoshi M., Aoyama M., Fueda Y., et al. Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutrition Research 2008, 28:321.
115. Vaahtovuo J., Munukka E., Korkeamaki M., Luukkainen R., Toivanen P. Fecal microbiota in early rheumatoid arthritis. The Journal of Rheumatology 2008, 35:1500.
116. Vangaveti V., Shashidhar V., Jarrod G., Baune B.T., Kennedy R.L. Free fatty acid receptors: Emerging targets for treatment of diabetes and its complications. Therapeutic Advances in Endocrinology and Metabolism 2010, 1:165.
117. Viatour P., Legrand-Poels S., van Lint C., Warnier M., Merville M.-P., Gielen J., et al. Cytoplasmic IκBα increases NF-κB-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3. Journal of Biological Chemistry 2003, 278:46541.
118. Vieira E.L., Leonel A.J., Sad A.P., Beltrao N.R., Costa T.F., Ferreira T.M., et al. Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. The Journal of Nutritional Biochemistry 2012, 23:430.
119. Villagra A., Cheng F., Wang H.W., Suarez I., Glozak M., Maurin M., et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nature Immunology 2009, 10:92.
120. Vinolo M.A., Rodrigues H.G., Hatanaka E., Hebeda C.B., Farsky S.H., Curi R. Short-chain fatty acids stimulate the migration of neutrophils to inflammatory sites. Clinical Science (London, England) 2009, 117:331.
121. Vinolo M.A., Rodrigues H.G., Hatanaka E., Sato F.T., Sampaio S.C., Curi R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. The Journal of Nutritional Biochemistry 2011, 22:849.
122. Voltolini C., Battersby S., Etherington S.L., Petraglia F., Norman J.E., Jabbour H.N. A novel antiinflammatory role for the short-chain fatty acids in human labor. Endocrinology 2012, 153:395.
123. Wakabayashi K., Saito H., Kaneko F., Nakamoto N., Tada S., Hibi T. Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor. International Journal of Oncology 2005, 26:233.
124. Waldecker M., Kautenburger T., Daumann H., Busch C., Schrenk D. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. The Journal of Nutritional Biochemistry 2008, 19:587.
125. Wanders D., Graff E.C., Judd R.L. Effects of high fat diet on GPR109A and GPR81 gene expression. Biochemical and Biophysical Research Communications 2012, 425:278.
126. Wen L., Ley R.E., Volchkov P.Y., Stranges P.B., Avanesyan L., Stonebraker A.C., et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008, 455:1109.
127. Westermann P., Ahring B.K., Mah R.A. Acetate production by methanogenic bacteria. Applied and Environmental Microbiology 1989, 55:2257.
128. Wong J.M., de Souza R., Kendall C.W., Emam A., Jenkins D.J. Colonic health: Fermentation and short chain fatty acids. Journal of Clinical Gastroenterology 2006, 40:235.
129. Wu J., Zhou Z., Hu Y., Dong S. Butyrate-induced GPR41 activation inhibits histone acetylation and cell growth. Journal of Genetics and Genomics 2012, 39:375.
130. Xiong Y., Miyamoto N., Shibata K., Valasek M.A., Motoike T., Kedzierski R.M., et al. Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:1045.
131. Zhang F., Shi Y., Wang L., Sriram S. Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. PLoS One 2011, 6:e16795.
132. oB determines its association with CBP/p300 or HDAC-1. Molecular cell 2002, 9:625.
133. Zoetendal E.G., Raes J., van den Bogert B., Arumugam M., Booijink C.C., Troost F.J., et al. The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. The ISME Journal 2012, 6:1415.